Observational studyEuropean journal of medical research2025
Dietary antioxidants and CKM-depression comorbidity: a primary analysis with a secondary evaluation of all-cause mortality using six machine learning algorithms.
Observational study in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Depression and risk of incident heart diseases among older adults at CKM stages 0-3: evidence from the China Health and Retirement Longitudinal Study.Annals of medicine · 2026Article
- Association of lipoprotein(a) and composite inflammatory indices with functional outcomes in acute ischemic stroke: a prospective cohort study.Lipids in health and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWe examined whether dietary antioxidant intake is associated with CKM-depression comorbidity (primary outcome) and all-cause mortality (secondary outcome) in US adults.
methodsIn an observational analysis of NHANES 2007-2010 with linked mortality, we defined the primary outcome as CKM-depression comorbidity and the secondary outcome as all-cause mortality. Predictors were selected using LASSO (linear models) and Boruta (tree-based models). Six classifiers (AdaBoost, GBDT, LGBM, RF, SVM, NB) were trained. Evaluation used stratified tenfold/nested cross-validation; all preprocessing, feature selection, and SMOTE were performed inside training folds only to avoid leakage. Discrimination metrics included ROC-AUC, PR-AUC, F1, MCC, recall, specificity; calibration was assessed on out-of-fold probabilities using Brier score and calibration slope/intercept, with reliability curves. Subsequently, associations were assessed using multivariate logistic regression (for comorbidities) and Cox proportional hazards models (for all-cause mortality). We used permutation-adjusted P-values for multiplicity, restricted cubic splines for dose-response, and Schoenfeld residuals for the proportional-hazards assumption. E-values quantified residual confounding.
resultsAmong ML models, LGBM performed best (test AUC = 0.978) with favorable calibration. In fully adjusted models, higher anthocyanidin intake was associated with lower odds of CKM-depression comorbidity: peonidin (OR = 0.716, 95% CI 0.572, 0.897), petunidin (OR = 0.749, 95% CI 0.633, 0.885), and total anthocyanidins (OR = 0.973, 95% CI 0.959, 0.988). For all-cause mortality, Cox models showed inverse associations for petunidin (HR = 0.936, 95% CI 0.900, 0.975) and total anthocyanidins (HR = 0.993, 95% CI 0.988, 0.998), whereas peonidin was not significant after permutation adjustment (HR = 0.964, 95% CI 0.929, 1.000). Restricted cubic splines suggested monotonic inverse trends; proportional-hazards tests showed no violations.
conclusionsSpecific anthocyanidins were cross-sectionally associated with lower CKM-depression comorbidity and, for petunidin and total anthocyanidins, with lower mortality hazard. Given the observational design and potential residual confounding, these findings should be interpreted as associations rather than causal or protective effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.